F 18 T807 Tau PET Imaging of Alzheimer's Disease

Part of paid clinical trials in St Louis, Missouri.

Sponsor
Tammie L. S. Benzinger, MD, PhD
Study ID
NCT02414347
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • F 18 T807 — DRUG
    Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.

Study Details

A single-center, open-label baseline controlled imaging study designed to assess whether brain tau fibril uptake of flortaucipir as measured by PET correlates with cognitive status of individuals with and without brain tau fibrils.

Key Dates

Start date
Oct 23, 2014
Status verified
Jun 2026
Primary completion
Oct 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
900 participants (estimated)

Arms

  • Arm: Experimental F 18 T807
    Participants will undergo a PET scan using the flortaucipir imaging tracer

Primary Outcome Measure

F 18 T807 Standard Uptake Value Ratios (SUVR) will be correlated with other imaging modalities (MRI, PET amyloid imaging) and cognitive performance. [ Time Frame: 5 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Washington University School of MedicineSt LouisMissouri63110
Kelley M Jackson
[email protected]
314-362-1558

Find similar trials in St Louis, MO

By condition
Alzheimer's disease
By specialty
NeurologyDementia careBrain disordersGeriatrics
By research site
Washington University School of Medicine· St Louis, MO

Related Studies